(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 38.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Nurix Therapeutics's revenue in 2023 is $68,611,000.On average, 7 Wall Street analysts forecast NRIX's revenue for 2024 to be $2,717,375,098, with the lowest NRIX revenue forecast at $1,663,679,242, and the highest NRIX revenue forecast at $3,880,301,440. On average, 6 Wall Street analysts forecast NRIX's revenue for 2025 to be $3,112,389,785, with the lowest NRIX revenue forecast at $2,466,416,603, and the highest NRIX revenue forecast at $4,137,371,410.
In 2026, NRIX is forecast to generate $10,607,143,513 in revenue, with the lowest revenue forecast at $2,490,183,449 and the highest revenue forecast at $24,916,385,622.